Antitumour, acute toxicity and molecular modeling studies of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one against Ehrlich ascites carcinoma and sarcoma-180-Reference-Cited by-同舟云学术

Antitumour, acute toxicity and molecular modeling studies of 4-(pyridin-4-yl)-6-(thiophen-2-yl) pyrimidin-2(1H)-one against Ehrlich ascites carcinoma and sarcoma-180

Published:2018-06 Issue:6 Volume:4 Page:e00661
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Kumar Dinesh,Sharma Pooja,Nepali Kunal,Mahajan Girish,Mintoo Mubashir J.,Singh Amarinder,Singh Gurpreet,Mondhe Dilip M.,Singh Gurdarshan,Jain Subheet K.,Gupta Girish K.,Ntie-Kang Fidele^ORCID

Funder

University Grants Commission

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference59 articles.

1. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells;Pal;Biochem. Biophys. Res. Commun.,2001

2. Introduction to cancer chemotherapeutics;Shewach;Chem. Rev.,2009

3. New anticancer agents: in vitro and in vivo evaluation;Zips;In Vivo,2005

4. Establishment of a new co-culture model using negatively-charged slides;Vrekoussis;In Vivo,2004

5. Animal systems for translational research in radiation oncology;Taghian;Acta Oncol.,1999

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical Characterization of Corydalis chaerophylla D.C. Extracts and Preliminary Evaluation of Their in Vitro and in Vivo Biological Properties;Chemistry & Biodiversity;2023-11-14

2. Phytochemistry and Polypharmacological Potential of Colebrookea oppositifolia Smith;Current Topics in Medicinal Chemistry;2023-02

3. The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer;Frontiers in Pharmacology;2022-10-26

4. Phytochemical and In Vitro Cytotoxic Screening of Chloroform Extract of Ehretia microphylla Lamk;Stresses;2022-10-03

5. Mechanistic Insights and Docking Studies of Phytomolecules as Potential Candidates in the Management of Cancer;Current Pharmaceutical Design;2022-09